Antibody-drug Conjugates in the Clinic: Key Considerations & the Role of Modeling in Expediting Development
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…
Certara2023 年 4 月 17 日
Stepwise PIPs: A Solution for the Challenges of Pediatric Drug Development
Early paediatric investigation plan (PIP) submissions – an unnecessarily bitter medicine? In the European Union…
Certara2023 年 4 月 14 日
Why Performing Key CMC Activities Early Can Aid De-risking Your Drug Development Program
This white paper focuses on best practices for developing a CMC strategy for orally administered…
Certara2023 年 4 月 13 日
Drug Discovery & Development with Deep Learning Advanced Analytics
Solutions to Meet All Needs: From Small Biotech to Large Global Pharma
Certara2023 年 4 月 6 日
Considerations for Pricing & Formulary Access for DRG-Funded Hospital Drugs
In the United States, treatments or medical services that require the patient be admitted into…
Certara2023 年 4 月 6 日
Using Quantitative Systems Pharmacology Modelling to Accelerate Drug Development
Model informed drug development (in silico modelling) continues to be a game changer in accelerating…
Certara2023 年 3 月 29 日
Model-Informed Drug Development (MIDD) – EMA’s Advancement
Modelling and simulation (M&S) plays a crucial role in drug development. It allows information from…
Certara2023 年 3 月 29 日
Advancing Biopharmaceutics & Drug Formulation Using In Silico Modeling
模型引导的制剂开发（MIFD）提升新药与仿制药开发速度与确定性
Certara2023 年 3 月 22 日
